U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07413757) titled 'CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC' on Feb. 09.
Brief Summary: This non-interventional, cross-sectional study aims to investigate treatment preferences from a sample of physicians and patients with experience of 1L EGFR-TKI for stage IV NSCLC by administering a survey, which primarily includes a DCE approach.
Study Start Date: April 13
Study Type: OBSERVATIONAL
Condition:
Non-Small Cell Lung Cancer
Recruitment Status: NOT_YET_RECRUITING
Sponsor: AstraZeneca
Disclaimer: Curated by HT Syndication....